Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/30711279/ below:

Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma

Comparative Study

Affiliations

• ¹ Division of General Thoracic Surgery, Department of Surgery, Baylor College of Medicine, Houston, Tex. Electronic address: Shawn.Groth@bcm.edu.
• ² Division of General Thoracic Surgery, Department of Surgery, Baylor College of Medicine, Houston, Tex.
• ³ Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash.
• ⁴ Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex.
• ⁵ Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Tex; Division of Surgical Oncology, Department of Surgery, Baylor College of Medicine, Houston, Tex.

• PMID: 30711279
• DOI: 10.1016/j.jtcvs.2018.11.131

Item in Clipboard

Comparative Study

Shawn S Groth et al. J Thorac Cardiovasc Surg. 2019 Apr.

• ¹ Division of General Thoracic Surgery, Department of Surgery, Baylor College of Medicine, Houston, Tex. Electronic address: Shawn.Groth@bcm.edu.
• ² Division of General Thoracic Surgery, Department of Surgery, Baylor College of Medicine, Houston, Tex.
• ³ Division of Cardiothoracic Surgery, Department of Surgery, University of Washington School of Medicine, Seattle, Wash.
• ⁴ Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Tex.
• ⁵ Center for Innovations in Quality, Effectiveness and Safety, Michael E. DeBakey VA Medical Center, Houston, Tex; Division of Surgical Oncology, Department of Surgery, Baylor College of Medicine, Houston, Tex.

• PMID: 30711279
• DOI: 10.1016/j.jtcvs.2018.11.131

Item in Clipboard

Objective: To determine the association between neoadjuvant chemotherapy and chemoradiation therapy on completeness of pathologic response and to assess the impact of primary tumor versus nodal response on survival after esophagectomy.

Methods: Patients aged 18 to 80 years in the National Cancer Data Base (2006-2016) with clinically staged, locally advanced (cT2-4 or cN+) esophageal adenocarcinoma who underwent an R0 esophagectomy after neoadjuvant chemotherapy or chemoradiation therapy were included. Multivariable Cox proportional hazards regression models were constructed to assess the association between treatment response and survival.

Results: Among 2870 patients, there was a significant dose-response association between completeness of response and overall survival: no response (reference), partial response (hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.72-0.91), and complete response (HR, 0.55; 95% CI, 0.47-0.65). Compared with neoadjuvant chemotherapy alone, neoadjuvant chemoradiation was associated with higher pathologic primary tumor (33.9% vs 21.3%; P < .001) and pathologic nodal response rates (55.9% vs 32.7%; P < .001). Both a primary and nodal response were associated with improved survival. However, among patients with a primary but no nodal response, primary tumor response was not associated with risk of death (HR, 0.88; 95% CI, 0.69-1.11). In contrast, among patients who had a nodal but no primary response, the survival benefit of a nodal response was maintained (HR, 0.66; 95% CI, 0.58-0.76).

Conclusions: Pathologic nodal (rather than primary tumor) response to neoadjuvant therapy is associated with improved survival. These data suggest a need to optimize neoadjuvant strategies associated with more complete nodal response rates and to consider more aggressive adjuvant treatment for patients with residual nodal disease after esophagectomy.

Keywords: esophageal neoplasms; esophagectomy; neoadjuvant therapy; pathology.

Copyright © 2018 The American Association for Thoracic Surgery. All rights reserved.

PubMed Disclaimer

• Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer.

  Burt BM, Groth SS, Sada YH, Farjah F, Cornwell L, Sugarbaker DJ, Massarweh NN. Burt BM, et al. Ann Surg. 2017 Aug;266(2):297-304. doi: 10.1097/SLA.0000000000001954. Ann Surg. 2017. PMID: 27501170

• Adjuvant chemotherapy for patients with pathologic node-positive esophageal cancer after induction chemotherapy is associated with improved survival.

  Samson P, Puri V, Lockhart AC, Robinson C, Broderick S, Patterson GA, Meyers B, Crabtree T. Samson P, et al. J Thorac Cardiovasc Surg. 2018 Oct;156(4):1725-1735. doi: 10.1016/j.jtcvs.2018.05.100. Epub 2018 Jun 28. J Thorac Cardiovasc Surg. 2018. PMID: 30054137

• Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer.

  Tiesi G, Park W, Gunder M, Rubio G, Berger M, Ardalan B, Livingstone A, Franceschi D. Tiesi G, et al. J Surg Res. 2017 Aug;216:65-72. doi: 10.1016/j.jss.2017.03.022. Epub 2017 Mar 31. J Surg Res. 2017. PMID: 28807215

• Esophagectomy after chemoradiation: who and when to operate.

  Kim JY, Hofstetter WL. Kim JY, et al. Semin Thorac Cardiovasc Surg. 2012 Winter;24(4):288-93. doi: 10.1053/j.semtcvs.2012.10.005. Semin Thorac Cardiovasc Surg. 2012. PMID: 23465677 Review.

• Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer.

  Blum Murphy MA, Elimova E, Ajani JA. Blum Murphy MA, et al. Expert Rev Gastroenterol Hepatol. 2016;10(3):383-92. doi: 10.1586/17474124.2016.1116936. Epub 2015 Dec 2. Expert Rev Gastroenterol Hepatol. 2016. PMID: 26560689 Review.

• Treatment of Anastomotic Recurrence After Esophagectomy.

  Carr RA, Harrington C, Vos E, Bains MS, Bott MJ, Isbell JM, Park BJ, Sihag S, Jones DR, Molena D. Carr RA, et al. Ann Thorac Surg. 2022 Aug;114(2):418-425. doi: 10.1016/j.athoracsur.2021.07.101. Epub 2021 Sep 10. Ann Thorac Surg. 2022. PMID: 34509415 Free PMC article.

• A More Extensive Lymphadenectomy Enhances Survival After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Adenocarcinoma.

  Sihag S, Nobel T, Hsu M, Tan KS, Carr R, Janjigian YY, Tang LH, Wu AJ, Bott MJ, Isbell JM, Bains MS, Jones DR, Molena D. Sihag S, et al. Ann Surg. 2022 Aug 1;276(2):312-317. doi: 10.1097/SLA.0000000000004479. Epub 2020 Nov 17. Ann Surg. 2022. PMID: 33201124 Free PMC article.

• Postoperative Adjuvant Therapy Benefits Non-pCR Patients Rather Than pCR Patients for Locally Advanced ESCC: A Multicenter Real-World Study.

  Liu D, Liu A, Guo L, Li Y, Li Y, Chi Y, Lin H, Yu J, Li M. Liu D, et al. Thorac Cancer. 2025 Feb;16(4):e70021. doi: 10.1111/1759-7714.70021. Thorac Cancer. 2025. PMID: 39988453 Free PMC article.

• Review of MR-Guided Radiotherapy for Esophageal Cancer.

  Lee SL, Bassetti M, Meijer GJ, Mook S. Lee SL, et al. Front Oncol. 2021 Mar 22;11:628009. doi: 10.3389/fonc.2021.628009. eCollection 2021. Front Oncol. 2021. PMID: 33828980 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3